Cipher Pharmaceuticals Inc. (TSX:CPH)
12.57
-0.41 (-3.16%)
Mar 28, 2025, 4:00 PM EST
Cipher Pharmaceuticals Revenue
In the year 2024, Cipher Pharmaceuticals had annual revenue of $33.36M USD with 57.66% growth. Cipher Pharmaceuticals had revenue of $11.82M in the quarter ending December 31, 2024, with 140.28% growth.
Revenue
$33.36M
Revenue Growth
+57.66%
P/S Ratio
6.47
Revenue / Employee
$6.67M
Employees
5
Market Cap
321.97M CAD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 33.36M | 12.20M | 57.66% |
Dec 31, 2023 | 21.16M | 487.00K | 2.36% |
Dec 31, 2022 | 20.68M | -1.27M | -5.78% |
Dec 31, 2021 | 21.94M | 336.00K | 1.56% |
Dec 31, 2020 | 21.61M | -844.00K | -3.76% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCipher Pharmaceuticals News
- 1 day ago - Cannabis Stock Gainers And Losers From March 27, 2025 - Benzinga
- 9 days ago - Cipher Pharmaceuticals Inc (CPHRF) Q4 2024 Earnings Call Highlights: Record Revenue Surge and ... - GuruFocus
- 9 days ago - Marijuana Stock Movers For March 19, 2025 - Benzinga
- 9 days ago - Cipher Pharmaceuticals GAAP EPS of $0.13, revenue of $11.82M misses by $0.28M - Seeking Alpha
- 9 days ago - Cipher Pharmaceuticals Inc. 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 9 days ago - Cipher Pharmaceuticals Inc. (CPHRF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Cipher Pharmaceuticals GAAP EPS of $0.13 misses by $0.02, revenue of $11.82M misses by $0.43M - Seeking Alpha
- 2 months ago - Jesse Gamble's Top Picks: Zedcor, Enterprise Group and Cipher Pharmaceuticals - BNN Bloomberg